Xu, Shilin
Zhang, Meichen
Fang, Xiaocui
Meng, Jie
Xing, Haiyan
Yan, Doudou
Liu, Jian
Yang, Yanlian
Wen, Tao
Zhang, Weiqi
Wang, Jianxiang
Wang, Chen
Xu, Haiyan
Funding for this research was provided by:
National Key R&D Program of China (2017YFA0205504)
CAMS Innovation Fund for Medical Science (2016-I2M-3-004)
National Natural Science Foundation of China (51861135103, 21721002)
Key Research Program of Frontier Sciences, Chinese Academy of Science (QYZDJ-SSW-SLH048)
Article History
Received: 20 September 2021
Accepted: 29 October 2021
First Online: 13 November 2021
Declarations
:
: The bone marrow samples were obtained from two patients diagnosed as refractory AML, who were enrolled in the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. This subject was approved by the ethical committee in the Institute of Hematology and Blood Diseases Hospital and all procedures in accordance with the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations.
: The content of this manuscript has not been previously published and is not under consideration for publication elsewhere.
: The authors declare that they have no competing interests.